{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:09Z","timestamp":1792205229609,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.blre.2025.101355","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:28Z","timestamp":1764345748000},"page":"101355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications"],"prefix":"10.1016","volume":"75","author":[{"given":"Idoroenyi","family":"Amanam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ghoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9464","key":"10.1016\/j.blre.2025.101355_bb0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101355_bb0010","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101355_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0020","first-page":"510","article-title":"Molecular mutations and prognosis in primary myelofibrosis","volume":"131","author":"Vannucchi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0025","first-page":"136","article-title":"Pathogenesis and management of myelofibrosis","volume":"2016","author":"Tefferi","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"13","key":"10.1016\/j.blre.2025.101355_bb0030","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101355_bb0040","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101355_bb0045","first-page":"649","article-title":"Therapeutic potential of JAK2 inhibitors","volume":"2010","author":"Verstovsek","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0050","first-page":"333","article-title":"Hematopoietic stem cell mobilization and extramedullary hematopoiesis in myelofibrosis","volume":"49","author":"Mascarenhas","year":"2012","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.1840120515","article-title":"Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.leu.2404943","article-title":"Pulmonary arterial hypertension in primary myelofibrosis is common and associated with altered angiogenic status","volume":"22","author":"Cortelezzi","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.blre.2025.101355_bb0065","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101355_bb0070","first-page":"530","article-title":"Allogeneic stem cell transplantation in myelofibrosis","volume":"32","author":"Robin","year":"2018","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.blre.2025.101355_bb0075","first-page":"1933","article-title":"Modern management of splenomegaly in myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep.1840170214","article-title":"Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations","volume":"17","author":"Dubois","year":"1993","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0085","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.22772","article-title":"Vascular disorders of the liver","volume":"49","author":"DeLeve","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0090","first-page":"1013","article-title":"Portal hypertension and variceal bleeding \u2014 unresolved issues","volume":"47","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.blre.2025.101355_bb0095","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0100","first-page":"171","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0110","first-page":"1106","article-title":"The window of opportunity for transjugular intrahepatic portosystemic shunt in patients with cirrhosis","volume":"61","author":"Reiberger","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2017.02.003","article-title":"Non-invasive evaluation of portal hypertension using ultrasound elastography","volume":"67","author":"Berzigotti","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.blre.2025.101355_bb0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101355_bb0125","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3748\/wjg.v21.i8.2534","article-title":"Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: A meta-analysis","volume":"21","author":"Dai","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20559","article-title":"The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension","volume":"41","author":"Boyer","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.blre.2025.101355_bb0140","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Francesco","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0150","first-page":"799","article-title":"Risk factors for thrombosis in essential thrombocythemia: a study of 891 patients","volume":"111","author":"Carobbio","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101355_bb0155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101355_bb0160","first-page":"777","article-title":"Portal vein thrombosis and mesenteric vein thrombosis: a retrospective review of aetiologies, the role of prothrombotic states and the impact of therapy","volume":"16","author":"Al-Mukhaizeem","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101355_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-139229","article-title":"Direct Oral anticoagulants for myeloproliferative neoplasms (MPN-DOACs): results from an international study on 442 patients","volume":"136","author":"Barbui","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0170","article-title":"Extramedullary hematopoiesis in myelofibrosis: pathophysiology, clinical manifestations and treatment strategies","volume":"9","author":"Patriarca","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"10.1016\/j.blre.2025.101355_bb0175","first-page":"293","article-title":"Myeloproliferative neoplasms: complications, management, and therapy","volume":"28","author":"Verstovsek","year":"2014","journal-title":"Blood Rev"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0180","first-page":"1693","article-title":"Non-selective beta blockers in portal hypertension: evidence and mechanisms","volume":"61","author":"Reiberger","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.blre.2025.101355_bb0185","first-page":"933","article-title":"Variceal bleeding in portal hypertension secondary to MPN","volume":"45","author":"Zafra","year":"2013","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0190","first-page":"1322","article-title":"Endoscopic therapy in variceal bleeding: ligation versus sclerotherapy","volume":"112","author":"Loffredo","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2025.101355_bb0195","first-page":"27","article-title":"Direct oral anticoagulants in MPN: a multi-center real-world study","volume":"190","author":"Rungjirajittranon","year":"2020","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101355_bb0200","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/leu.2014.5","article-title":"Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis","volume":"28","author":"Tabarroki","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2169\/internalmedicine.3528-19","article-title":"Long-term effects of the Janus Kinase 1\/2 inhibitor ruxolitinib on pulmonary hypertension and the cardiac function in a patient with myelofibrosis","volume":"59","author":"Miyawaki","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.blre.2025.101355_bb0210","first-page":"1","article-title":"Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis","author":"Amanam","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101355_bb0215","first-page":"W45","article-title":"Pulmonary extramedullary hematopoiesis in myelofibrosis: imaging findings and clinical implications","volume":"30","author":"Chen","year":"2015","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.blre.2025.101355_bb0220","first-page":"963","article-title":"Detection of pulmonary extramedullary hematopoiesis with nuclear imaging techniques","volume":"31","author":"Wagner","year":"2010","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.blre.2025.101355_bb0225","article-title":"Role of angiogenesis in myeloproliferative neoplasm-associated pulmonary hypertension","volume":"9","author":"Patel","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.blre.2025.101355_bb0230","first-page":"1651","article-title":"Prevalence and prognostic impact of pulmonary hypertension in myelofibrosis","volume":"54","author":"Gangat","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101355_bb0235","first-page":"1269","article-title":"Pulmonary hypertension and myeloproliferative disorders","volume":"40","author":"Montani","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0240","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.blre.2025.101355_bb0245","first-page":"984","article-title":"Dyspnea as a presenting symptom of pulmonary hypertension in myeloproliferative neoplasms","volume":"86","author":"Gertz","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101355_bb0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101355_bb0255","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.blre.2025.101355_bb0260","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101355_bb0265","first-page":"230","article-title":"Liver injury after hematopoietic stem cell transplantation: current perspectives","volume":"16","author":"Vigorito","year":"2022","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0270","first-page":"333","article-title":"Hepatic sinusoidal obstruction syndrome in the transplant setting","volume":"20","author":"Mohty","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.blre.2025.101355_bb0275","first-page":"2145","article-title":"Management of organ toxicities in myelofibrosis patients undergoing allogeneic transplant","volume":"56","author":"Kroger","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2025.101355_bb0280","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2025.101355_bb0285","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic Veno-occlusive disease: final results from the international compassionate-use program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0290","first-page":"e27","article-title":"Defibrotide in prevention and treatment of veno-occlusive disease after stem cell transplant","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41409-019-0741-8","article-title":"Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"55","author":"Gupta","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2025.101355_bb0300","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101355_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101355_bb0310","first-page":"S1","article-title":"Hematopoietic cell transplantation: practice recommendations and new perspectives","volume":"27","author":"Copelan","year":"2021","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2025.101355_bb0315","first-page":"473","article-title":"Inflammatory pathways and complications in myeloproliferative neoplasms","volume":"32","author":"Barbui","year":"2018","journal-title":"Blood Rev"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101355_bb0320","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1200\/JCO.2024.42.16_suppl.6558","article-title":"Impact of spleen volume on post-allogeneic hematopoietic transplant outcomes in myelofibrosis: utility of 3D volumetrics in splenomegaly","volume":"42","author":"Haseeb","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101355_bb0325","first-page":"1958","article-title":"Ruxolitinib for GvHD prevention in myelofibrosis transplant recipients: a pilot study","volume":"55","author":"Ali","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2025.101355_bb0330","first-page":"456","article-title":"Pathophysiology of acute and chronic graft-versus-host disease","volume":"21","author":"Zeiser","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2025.101355_bb0335","first-page":"1","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.blre.2025.101355_bb0340","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101355_bb0345","article-title":"IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R\/R) to Janus kinase inhibitors (JAKi)","volume":"43","author":"Mascarenhas","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101355_bb0350","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/bloodadvances.2023011653","article-title":"Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization","volume":"8","author":"Cancilla","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:16:34Z","timestamp":1772511394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":70,"alternative-id":["S0268960X25001006"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101355","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101355"}}